1. Russian Federation Stocks

  2. •

    Healthcare

  3. •

    Medical - Care Facilities
International Medical Center of Biomaterials Processing and Cryostorage Public Joint-stock company

International Medical Center of Biomaterials Processing and Cryostorage Public Joint-stock company

GEMA.ME
International Medical Center of Biomaterials Processing and Cryostorage Public Joint-stock companyRU flagMoscow Stock Exchange
108.40
RUB
-1.40
- -
1.62BMarket Cap
International Medical Center of Biomaterials Processing and Cryostorage Public Joint-stock company
GEMA.ME
(Moscow Stock Exchange)

Recent

price

108.40

P/E

ratio

- -

div

yld

- -

ROIC.AI

2016
2017
2018
2019
2020
2021
2022
2023
TTM
FRC
- -
16.68
19.12
17.76
16.25
17.81
17.06
- -
8.8
Revenue per Share
- -
10.46
11.17
8.88
8.22
9.14
6.58
- -
3.75
Basic EPS, GAAP
- -
8.66
12.85
8.42
8.86
15.97
16.16
- -
- -
Free Cash Flow per Basic Share
- -
9.41
11.89
6.21
5.7
10.06
9.45
- -
- -
Dividend per Share
- -
3.88
3.16
3.1
3.71
3.14
3.63
- -
5.03
Book Value per Share
- -
3.87
3.18
12.08
11.88
11.66
3.28
- -
33.56
Tangible Book Value per Share
- -
13
13
13
15
15
15
- -
15
Basic Weighted Avg Shares
- -
212
243
239
243
266
255
284
131
Sales/Revenue/Turnover
- -
61.95
58.04
55.19
54.64
52.06
50.39
52.72
31.38
Operating Margin (%)
- -
5
6
5
10
8
1
1
- -
Depreciation Expense
- -
133
142
119
123
136
98
126
56
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
62.71
58.43
49.98
50.6
51.34
38.55
44.36
42.56
Profit Margin (%)
-34
5
-9
16
3
425
-7
64
18
Working Capital
- -
- -
1
31
58
59
253
246
228
LT Debt
36
53
44
196
210
202
139
441
590
Total Equity
- -
298.86
348.44
102.33
53.28
54.86
43.06
29.23
7.44
Return on Invested Capital (%)
- -
307.3
311.01
214.93
137.55
127.67
55.43
52.9
30.79
Return on Capital (%)
- -
312.18
317.61
291.97
253.16
266.84
194.14
287.24
72.46
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'22
Dec'22
Mar'23
ST Debt
- -
2
5
LT Borrowings
230
228
- -
LT Finance Leases
- -
20
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
15
1
15
Market Capitalization
- -
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Sep'22
Dec'22
Mar'23
Total Current Assets
110
137
155
Cash, Cash Equivalents & STI
66
81
88
Accounts Receivable, Net
39
47
62
Inventories
6
5
5
Total Current Liabilities
163
152
137
Payables & Accruals
- -
- -
- -
ST Debt
- -
2
5
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
106.45%
216.24%
Free Cash Flow
- -
- -
- -
Net Income, GAAP
- -
-0.34%
28.13%
Sales/Revenue/Turnover
- -
3.34%
11.32%
Total Cash Common Dividend
- -
2.94%
-12.99%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
64
66
68
68
266
2022
66
- -
- -
62
255
2023
69
- -
70
- -
284

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
2.49
- -
- -
- -
9.14
2022
2.3
- -
- -
- -
6.58
2023
2.3
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
10.06
2022
- -
- -
- -
- -
9.45
2023
- -
- -
- -
- -
- -
Similar Companies
FamiCord AG (V3V.DE)
PAO Group, Inc. (PAOG)
Mediclinic International plc (MEI.JO)
Cryo-Cell International, Inc. (CCEL)
Kt Medical Service Public Company Limited (KTMS.BK)
Fresenius SE & Co. KGaA (FRE.SW)
Business
International Medical Center of Biomaterials Processing and Cryostorage Public Joint-stock company, known as Gemabank, functions as a prominent licensed institution specializing in the private storage of cord blood stem cells and umbilical cord tissue across Russia and the Commonwealth of Independent States. The biotechnology enterprise, established in 2003 and headquartered in Moscow, Russia, facilitates bioinsurance services and actively engages in research for advanced gene therapy treatments. The company has demonstrated solid financial performance, reporting a 5.7% increase in net profit and a 20.3% rise in revenue for the first nine months of 2024. This entity operates as a subsidiary of Human Stem Cells Institute PJSC.